Is duodenal biopsy required in all patients with suspected celiac disease?

Proportion of cancers due to occupation. Prev Med (1980) 1.82

Celiac sprue. N Engl J Med (2002) 7.12

Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile. Clin Infect Dis (2001) 6.92

Body-mass index and symptoms of gastroesophageal reflux in women. N Engl J Med (2006) 5.24

ACG clinical guidelines: diagnosis and management of celiac disease. Am J Gastroenterol (2013) 4.36

A mouse model of Clostridium difficile-associated disease. Gastroenterology (2008) 3.65

Interruption of recurrent Clostridium difficile-associated diarrhea episodes by serial therapy with vancomycin and rifaximin. Clin Infect Dis (2007) 3.15

Prospective derivation and validation of a clinical prediction rule for recurrent Clostridium difficile infection. Gastroenterology (2008) 2.50

Underlying disease severity as a major risk factor for nosocomial Clostridium difficile diarrhea. Infect Control Hosp Epidemiol (2002) 1.94

Serum anti-toxin B antibody correlates with protection from recurrent Clostridium difficile infection (CDI). Vaccine (2009) 1.85

Association between IgG2 and IgG3 subclass responses to toxin A and recurrent Clostridium difficile-associated disease. Clin Gastroenterol Hepatol (2007) 1.70

Microscopic colitis. Gastroenterology (2011) 1.66

Clostridium difficile toxoid vaccine in recurrent C. difficile-associated diarrhea. Gastroenterology (2005) 1.62

Fecal microbiota transplantation--an old therapy comes of age. N Engl J Med (2013) 1.50

Application of isothermal helicase-dependent amplification with a disposable detection device in a simple sensitive stool test for toxigenic Clostridium difficile. J Mol Diagn (2008) 1.41

Kinetics of the histological, serological and symptomatic responses to gluten challenge in adults with coeliac disease. Gut (2012) 1.37

Saccharomyces boulardii produces a soluble anti-inflammatory factor that inhibits NF-kappaB-mediated IL-8 gene expression. Biochem Biophys Res Commun (2006) 1.26

Saccharomyces boulardii inhibits ERK1/2 mitogen-activated protein kinase activation both in vitro and in vivo and protects against Clostridium difficile toxin A-induced enteritis. J Biol Chem (2006) 1.25

Clostridium difficile vaccine and serum immunoglobulin G antibody response to toxin A. Infect Immun (2003) 1.18

Clostridium difficile infection in the inflammatory bowel disease patient. Inflamm Bowel Dis (2013) 1.09

Human antibody response to surface layer proteins in Clostridium difficile infection. FEMS Immunol Med Microbiol (2004) 1.06

Comparative efficacies of rifaximin and vancomycin for treatment of Clostridium difficile-associated diarrhea and prevention of disease recurrence in hamsters. Antimicrob Agents Chemother (2008) 1.05

MIP-3alpha neutralizing monoclonal antibody protects against TNBS-induced colonic injury and inflammation in mice. Am J Physiol Gastrointest Liver Physiol (2007) 1.00

Topical antisense oligonucleotide therapy against LIX, an enterocyte-expressed CXC chemokine, reduces murine colitis. Am J Physiol Gastrointest Liver Physiol (2005) 0.99

Saccharomyces boulardii interferes with Shigella pathogenesis by postinvasion signaling events. Am J Physiol Gastrointest Liver Physiol (2007) 0.95

Saccharomyces boulardii inhibits EGF receptor signaling and intestinal tumor growth in Apc(min) mice. Gastroenterology (2009) 0.90

Mortality in patients with Clostridium difficile infection correlates with host pro-inflammatory and humoral immune responses. J Med Microbiol (2013) 0.90

A prospective study of risk factors and historical trends in metronidazole failure for Clostridium difficile infection. Clin Gastroenterol Hepatol (2008) 0.90

Human monoclonal antibodies against Clostridium difficile toxins A and B inhibit inflammatory and histologic responses to the toxins in human colon and peripheral blood monocytes. Antimicrob Agents Chemother (2013) 0.89

Refractory celiac disease. Curr Gastroenterol Rep (2007) 0.88

Macrophage-inflammatory protein-3alpha mediates epidermal growth factor receptor transactivation and ERK1/2 MAPK signaling in Caco-2 colonic epithelial cells via metalloproteinase-dependent release of amphiregulin. J Immunol (2007) 0.88

Update on the immunologic basis of Helicobacter pylori gastritis. Curr Opin Gastroenterol (2004) 0.88

Toll-like receptor 5-dependent immunogenicity and protective efficacy of a recombinant fusion protein vaccine containing the nontoxic domains of Clostridium difficile toxins A and B and Salmonella enterica serovar typhimurium flagellin in a mouse model of Clostridium difficile disease. Infect Immun (2013) 0.86

MBX-500, a hybrid antibiotic with in vitro and in vivo efficacy against toxigenic Clostridium difficile. Antimicrob Agents Chemother (2012) 0.85

Celiac disease and gastroesophageal reflux disease: yet another presentation for a clinical chameleon. Clin Gastroenterol Hepatol (2010) 0.83

Gastrointestinal cancer in celiac disease: "the first days are the hardest days, don't you worry anymore?". Clin Gastroenterol Hepatol (2011) 0.81

Quantifying gastric Helicobacter pylori infection: a comparison of quantitative culture, urease breath testing, and histology. Dig Dis Sci (2007) 0.78

Celiac sprue. Semin Gastrointest Dis (2002) 0.78

Reflux, dyspepsia, and disorders of the foregut. South Med J (2007) 0.75

Large intestine. Curr Opin Gastroenterol (2012) 0.75

Aspects of large intestinal health and disease. Curr Opin Gastroenterol (2013) 0.75

Large intestine. Curr Opin Gastroenterol (2011) 0.75

Socioeconomic Risk Factors for Celiac Disease Burden and Symptoms. J Clin Gastroenterol (2016) 0.75